The ELIXA biomarker study evaluated protein biomarkers as clinical risk factors to identify people with type 2 diabetes and acute coronary syndrome who are at highest risk for cardiovascular (CV) outcomes and death. Professor Hertzel Gerstein (McMaster University, Hamilton, ON, Canada) discusses the outcomes of the ELIXA biomarker study and the implications of the findings for clinical practice.
The abstract entitled ‘Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Please can you describe the rationale for investigating novel protein biomarkers as risk factors for cardiovascular outcomes? (0:27)
- How did the ELIXA biomarker study evaluate potential novel protein risk factors and what were its key findings? (1:42)
- In your opinion, what are the implications of these results for clinical practice? (3:12)
Disclosures: Hertzel Gerstein is on the advisory board and a consultant for Sanofi. Hertzel Gerstein has received grant/research support and honorarium from Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
Watch out for Danatech! The latest online resource for diabetes healthcare professionals
touchENDOCRINOLOGY spoke to Leslie Kolb (Chief Science Practice and Learning Officer) and Dana Moreau (Senior Product Manager of Danatech) from the Association of Diabetes Care and Education Specialists (ADCES) to discuss the exciting launch of Danatech. This innovative online resource allows healthcare professionals to research and review the latest devices and mobile apps and offers […]
Riccardo Candido, ADA 2022: Intensification strategies following GLP1-RA therapy failure in type 2 diabetes, the RESTORE-G real-world study
The RESTORE-G real-world study investigated the intensification strategies following GLP1-RA therapy failure in type 2 diabetes. Dr Riccardo Candido (Diabetes Center District 4, ASUGI, Trieste, Italy) discusses the design of the study, the key findings and the implications for clinical practice. The abstract entitled ‘Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 […]
Riccardo Candido, ADA 2022: GLP1-RA therapy for type 2 diabetes and the intensification strategies following treatment failure
Intensification strategies are available if patients with type 2 diabetes experience GLP1-RA therapy failure. Dr Riccardo Candido (Diabetes Center District 4, ASUGI, Trieste, Italy) discusses the current place of GLP1-RA therapy for the treatment of type 2 diabetes and the intensification strategies available following failure. Dr Riccardo Candido presented an abstract entitled ‘Treatment Intensification after […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!